Clinical Trial TitlePhase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer.
National Clinical Trial Number:NCT03775265
Clinical Trial Protocol Description:
This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle invasive bladder cancer. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as gemcitabine, cisplatin, fluorouracil and mitomycin-C, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with radiation therapy may kill more tumor cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab with radiation therapy and chemotherapy may work better in treating patients with localized muscle invasive bladder cancer compared to radiation therapy and chemotherapy without atezolizumab.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Have histologically proven T2-T4a N0M0 urothelial carcinoma of the baldder; mixed urothelial carcinoma will be eligible, but the presence of small cell carcinoma will make a patient ineligible.
- Have not received any systemic chemotherapy for their bladder cancer.
- Have not received prior pelvic radiation.
- Have not received any systemic therapy for non-muscle invasive bladder cancer.
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.